Cargando…

Guselkumab for the treatment of severe plaque psoriasis in a schizophrenia patient

A wide range of comorbid conditions are associated with psoriasis, many studies have drawn attention to a higher prevalence of psychiatric comorbidities in psoriatic population. Herein, we present a case of a Caucasian 44-years-old man suffering from a severe schizophrenia, who received guselkumab (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bernardini, Nicoletta, Skroza, Nevena, Prevete, Elisabeth, Marraffa, Federica, Proietti, Ilaria, Tolino, Ersilia, Mambrin, Alessandra, Rossi, Giovanni, Volpe, Salvatore, Bersani, Giuseppe, Potenza, Concetta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	PAGEPress Publications, Pavia, Italy 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724714/ https://www.ncbi.nlm.nih.gov/pubmed/36483220 http://dx.doi.org/10.4081/dr.2022.9476

Ejemplares similares

A case of twins affected by psoriasis, psoriatic arthritis and autism: Five years of efficacious and safe treatment with Secukinumab
por: Bernardini, Nicoletta, et al.
Publicado: (2022)

Long term efficacy, safety, and tolerability of tildrakizumab in epileptic patient with psoriasis and eczema
por: Bernardini, Nicoletta, et al.
Publicado: (2022)

Safety and Impact of Anti-COVID-19 Vaccines in Psoriatic Patients Treated with Biologics: A Real Life Experience
por: Skroza, Nevena, et al.
Publicado: (2021)

Aesthetic Treatments in Cancer Patients
por: Proietti, Ilaria, et al.
Publicado: (2021)

Advantages of Tailored Isotretinoin Treatment in Moderate to Severe Acne: Real-Life Data
por: Skroza, Nevena, et al.
Publicado: (2021)

Long-Term Maintained Response to Selective Internal Radiation Therapy in an Oligometastatic Uveal Melanoma Patient Treated with Concomitant Anti-PD-1 Therapy
por: Proietti, Ilaria, et al.
Publicado: (2021)

A Case of Psoriatic Disease and Hidradenitis Suppurativa in a Child with Chromosome 17q21.31 Microduplication Syndrome
por: Tolino, Ersilia, et al.
Publicado: (2023)

Efficacy of Cemiplimab in a Patient Affected by Cutaneous Squamous Cell Carcinoma and Myelodysplastic Syndrome
por: Proietti, Ilaria, et al.
Publicado: (2023)

A Review of the Literature of Surgical and Nonsurgical Treatments of Invasive Squamous Cells Carcinoma
por: Potenza, Concetta, et al.
Publicado: (2018)

Do Diet and Lifestyles Play a Role in the Pathogenesis of NMSCs?
por: Skroza, Nevena, et al.
Publicado: (2020)

Correlations between Psoriasis and Inflammatory Bowel Diseases
por: Skroza, Nevena, et al.
Publicado: (2013)

Adverse skin reactions to personal protective equipment during COVID‐19 pandemic in Italian health care workers
por: Proietti, Ilaria, et al.
Publicado: (2022)

Factors influencing response to ingenol mebutate therapy for actinic keratosis of face and scalp
por: Skroza, Nevena, et al.
Publicado: (2017)

The Role of the Western Diet on Atopic Dermatitis: Our Experience and Review of the Current Literature
por: Ilaria, Proietti, et al.
Publicado: (2023)

Evaluation of Cardiovascular Risk in Hidradenitis Suppurativa Patients Using Heart Rate Variability (HRV) Analysis
por: Skroza, Nevena, et al.
Publicado: (2020)

IL‐17 and its role in inflammatory, autoimmune, and oncological skin diseases: state of art
por: Bernardini, Nicoletta, et al.
Publicado: (2019)

Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review
por: Proietti, Ilaria, et al.
Publicado: (2020)

BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions
por: Proietti, Ilaria, et al.
Publicado: (2020)

Eruptive Blue Nevi of the Scalp in a Patient with Mayer–Rokitansky–Küster–Hauser Syndrome during Isotretinoin Therapy
por: Skroza, Nevena, et al.
Publicado: (2019)

Clinical utility of ingenol mebutate in the management of actinic keratosis: perspectives from clinical practice
por: Skroza, Nevena, et al.
Publicado: (2018)

Management of psoriatic patients in biologic treatment associated with infectious comorbidities
por: Nicoletta, Bernardini, et al.
Publicado: (2020)

Guselkumab for plaque psoriasis
Publicado: (2019)

Cardiovascular risk evaluation through heart rate variability analysis in psoriatic patients before and after 24 weeks of etanercept therapy: Prospective study
por: Potenza, Concetta, et al.
Publicado: (2016)

Supraorbital Basosquamous Carcinoma Treated with Cemiplimab Followed by Sonidegib: A Case Report and Review of the Literature
por: Proietti, Ilaria, et al.
Publicado: (2023)

How lockdown measures, during COVID-19 pandemic, matter on psoriatic patient’s perception: Study on 600 patients on biologic therapy
por: Bernardini, N., et al.
Publicado: (2021)

A Case Report of Monkeypox in an Adult Patient from Italy: Clinical and Dermoscopic Manifestations, Diagnosis and Management
por: Proietti, Ilaria, et al.
Publicado: (2022)

Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis
por: Light, Jeremy G, et al.
Publicado: (2021)

Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis
por: Yang, Eric J, et al.
Publicado: (2019)

Arthritis Interception in Patients with Psoriasis Treated with Guselkumab
por: Zabotti, Alen, et al.
Publicado: (2021)

Real-world Data Reveal Long Drug Survival for Guselkumab in Patients with Plaque Psoriasis
por: VAN MUIJEN, Marloes E., et al.
Publicado: (2022)

Guselkumab for the treatment of psoriasis – evidence to date
por: Nogueira, Miguel, et al.
Publicado: (2019)

Drug survival of guselkumab in patients with plaque psoriasis: A 2 year retrospective, multicenter study
por: Lytvyn, Yuliya, et al.
Publicado: (2021)

Guselkumab Treatment Outcomes and Persistence in a Nationwide Real-world Cohort of Patients with Plaque Psoriasis
por: MÄLKÖNEN, Tarja, et al.
Publicado: (2022)

Effectiveness of Guselkumab Therapy among Patients with Plaque Psoriasis with Baseline IGA Score ≥ 2 in the CorEvitas Psoriasis Registry
por: Armstrong, April W., et al.
Publicado: (2022)

Eczematous eruption after guselkumab treatment for psoriasis
por: Reyn, Birgit, et al.
Publicado: (2019)

Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study
por: Galluzzo, Marco, et al.
Publicado: (2020)

Rapid Remission of Sunburn-Induced Guttate Psoriasis with Guselkumab
por: Bartholomew, Erin, et al.
Publicado: (2023)

Real-World Effectiveness of 9–12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry
por: Armstrong, April W., et al.
Publicado: (2022)

Assessing the Short-Term Efficacy and Safety of Guselkumab for Moderate-to-Severe Plaque Psoriasis: Meta-Analysis of Randomized Controlled Trials
por: Yang, Jing, et al.
Publicado: (2020)

Adjusted treatment COMPArisons between guSelkumab and uStekinumab for treatment of moderate‐to‐severe plaque psoriasis: the COMPASS analysis
por: Diels, J., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_o3sqmb254c5qbck1hc5u612ioq